Acutaas Reports Q2 Net Profit Of ₹1.34 Billion; Raises FY27 Revenue Forecast To 30%

Market snapshot: Acutaas Chemicals Limited has reported a strong performance for Q2 FY27, backed by a sharp jump in standalone net profit alongside an upward revision of its full-year guidance. Standalone net profit reached ₹134 crore (₹1.34 billion) compared to ₹73 crore (₹730 million) in the same period last fiscal. Management has simultaneously elevated its FY27 revenue growth target to approximately 30% and raised its EBITDA margin guidance to 38–40%.

Data Snapshot

• Q2 FY27 standalone net profit stood at ₹134 crore (₹1.34 billion), reflecting a growth of ≈83.56% YoY (derived: ₹134 crore vs ₹73 crore).
• Revised FY27 revenue growth target increased to approximately 30% from the prior estimate of 25%.
• EBITDA margin guidance for FY27 upgraded to a range of 38–40%.

What's Changed

• Q2 standalone net profit expanded by ≈83.56% YoY to ₹134 crore compared to ₹73 crore in Q2 FY26 (derived: ₹134 crore vs ₹73 crore).
• Full-year FY27 revenue growth forecast upgraded by 500 bps to ~30% from the previous expectation of 25%.
• Full-year EBITDA margin target increased to 38–40%, reflecting higher operating leverage and favorable high-margin product mix.

Key Takeaways

• Substantial bottom-line expansion demonstrates strengthening operating efficiencies and favorable product realizations in primary chemical segments.
• The upgrade in full-year revenue growth guidance to ~30% reflects strong order visibility across Contract Development and Manufacturing Organisation (CDMO) contracts.
• Margin guidance entering the 38–40% corridor highlights structural profitability improvement as high-margin specialty offerings scale up.

SAHI Perspective

Acutaas Chemicals is experiencing strong momentum driven by high-value specialty chemical lines and scaling CDMO long-term partnerships. The concurrent upward revision in revenue growth and EBITDA margin expectations signals strong operational visibility rather than temporary volume gains. Expanding margins toward 38–40% demonstrate effective operating leverage and pricing discipline.

Market Implications

The dual guidance upgrade provides positive valuation support for Acutaas Chemicals, likely enhancing earnings visibility across institutional estimates. Sustained margin expansion in specialty chemicals and API CDMO verticals strengthens the broader sector setup, highlighting superior momentum among specialized, backward-integrated chemical manufacturers.

Trading Signals

Market Bias: Bullish

Strong Q2 net profit growth to ₹134 crore (+83.56% YoY) combined with upgraded FY27 guidance (revenue growth to ~30% and EBITDA margins to 38–40%) provides fundamental momentum for the stock.

Overweight: Specialty Chemicals, Pharmaceutical CDMO & Intermediates

Trigger Factors:

• Sustained quarterly EBITDA margin delivery within or above the 38–40% guided range
• Commercialization progress across validated CDMO projects
• Ramp-up in battery materials and semiconductor chemical verticals

Time Horizon: Near-term (0-3 months)

Industry Context

India's specialty chemicals and CDMO sector continues to benefit from supply chain diversification by global pharmaceutical and tech majors. Companies scaling backward-integrated manufacturing and specialized capabilities in active pharmaceutical ingredients, battery additives, and electronics chemicals are seeing higher margin resilience.

Key Risks to Watch

• Potential raw material price volatility impacting chemical gross margin stability
• Execution delays in commercializing new high-value CDMO molecules
• Global regulatory changes or export tariff adjustments in key overseas markets

Recent Developments

Acutaas Chemicals recently reported strong commercial progress across its three growth verticals—CDMO, semiconductor chemicals, and battery materials. The company completed trial runs for its electrolyte additive battery chemicals plant and commenced commercial supplies, aiming for full capacity utilization over the medium term.

Closing Insight

Acutaas Chemicals' combination of strong quarterly profit growth and upgraded full-year guidance underlines a structural shift toward higher-value products. Continuous execution across its CDMO and advanced chemical engines positions the firm for persistent compounding.

High Performance Trading with SAHI.